Terminated PHASE2 INTERVENTIONAL 1-arm NCT00524667

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

Sponsor: CancerCare Manitoba

Interventions Valproic acid & fludarabine

Updated 5 times since 2017 Last updated: Jul 18, 2011 Started: Jan 31, 2008 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated due to poor accrual.

Other terminated trials from CancerCare Manitoba

See all terminations from CancerCare Manitoba

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. CancerCare Manitoba leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CancerCare Manitoba
The Leukemia and Lymphoma Society

Data source: CancerCare Manitoba

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winnipeg, Canada